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Vitamin A supplementation every 6 months with retinol 
in 1 million pre-school children in north India: DEVTA, 
a cluster-randomised trial
Shally Awasthi, Richard Peto, Simon Read, Sarah Clark, Vinod Pande, Donald Bundy, and the DEVTA (Deworming and Enhanced Vitamin A) team
Summary
Background In north India, vitamin A deﬁ ciency (retinol <0·70 μmol/L) is common in pre-school children and 2–3% die 
at ages 1·0–6·0 years. We aimed to assess whether periodic vitamin A supplementation could reduce this mortality.
Methods Participants in this cluster-randomised trial were pre-school children in the deﬁ ned catchment areas of 
8338 state-staﬀ ed village child-care centres (under-5 population 1 million) in 72 administrative blocks. Groups of four 
neighbouring blocks (clusters) were cluster-randomly allocated in Oxford, UK, between 6-monthly vitamin A (retinol 
capsule of 200 000 IU retinyl acetate in oil, to be cut and dripped into the child’s mouth every 6 months), albendazole 
(400 mg tablet every 6 months), both, or neither (open control). Analyses of retinol eﬀ ects are by block (36 vs 36 clusters). 
The study spanned 5 calendar years, with 11 6-monthly mass-treatment days for all children then aged 6–72 months. 
Annually, one centre per block was randomly selected and visited by a study team 1–5 months after any trial vitamin A 
to sample blood (for retinol assay, technically reliable only after mid-study), examine eyes, and interview caregivers. 
Separately, all 8338 centres were visited every 6 months to monitor pre-school deaths (100 000 visits, 25 000 deaths at 
ages 1·0–6·0 years [the primary outcome]). This trial is registered at ClinicalTrials.gov, NCT00222547.
Findings Estimated compliance with 6-monthly retinol supplements was 86%. Among 2581 versus 2584 children 
surveyed during the second half of the study, mean plasma retinol was one-sixth higher (0·72 [SE 0·01] vs 
0·62 [0·01] μmol/L, increase 0·10 [SE 0·01] μmol/L) and the prevalence of severe deﬁ ciency was halved (retinol 
<0·35 μmol/L 6% vs 13%, decrease 7% [SE 1%]), as was that of Bitot’s spots (1·4% vs 3·5%, decrease 2·1% [SE 0·7%]). 
Comparing the 36 retinol-allocated versus 36 control blocks in analyses of the primary outcome, deaths per child-care 
centre at ages 1·0–6·0 years during the 5-year study were 3·01 retinol versus 3·15 control (absolute reduction 
0·14 [SE 0·11], mortality ratio 0·96, 95% CI 0·89–1·03, p=0·22), suggesting absolute risks of death between ages 1·0 and 
6·0 years of approximately 2·5% retinol versus 2·6% control. No speciﬁ c cause of death was signiﬁ cantly aﬀ ected. 
Interpretation DEVTA contradicts the expectation from other trials that vitamin A supplementation would reduce 
child mortality by 20–30%, but cannot rule out some more modest eﬀ ect. Meta-analysis of DEVTA plus eight previous 
randomised trials of supplementation (in various diﬀ erent populations) yielded a weighted average mortality 
reduction of 11% (95% CI 5–16, p=0·00015), reliably contradicting the hypothesis of no eﬀ ect.
Funding UK Medical Research Council, USAID, World Bank (vitamin A donated by Roche).
Introduction
During the 1980s, several randomised trials were under-
taken of periodic high-dose vitamin A supplementation 
(eg, 200 000 IU retinol every 6 months) in various 
populations of children with widespread biochemical 
vitamin A deﬁ ciency (plasma retinol <0·70 μmol/L 
[20 mg/dL]), severe deﬁ ciency (retinol <0·35 μmol/L 
[10 mg/dL]), or high child mortality from infection.1–9 
Most reported signiﬁ cant reductions in child mortality 
(although two2,6 did not), and meta-analyses of all their 
results suggested that periodic vitamin A supple-
mentation could reduce child mortality by 20–30%,10–14 
mainly by reducing mortality from infective causes such 
as diarrhoea and measles.
Nevertheless, there remained some uncertainty about 
supplementation,15 and in many low-income popula-
tions in the 1990s few children received supple ments. 
The policy in India was to encourage vitamin A 
supplementation to prevent eye disease, but in many 
parts of the country this was not widely implemented.16
In India, the Integrated Child Development Service 
(ICDS) maintains a network of child-care centres, 
caring for children up to age 6 years and oﬀ ering the 
potential to deliver simple health interventions. In rural 
Uttar Pradesh in north India, our plans to use the ICDS 
infrastructure for a large cluster-randomised trial of 
the eﬀ ects of 6-monthly deworming with albendazole 
on pre-school child mortality were revised into plans 
for a factorial trial that would also evaluate the eﬀ ects 
on mortality of enhancing vitamin A coverage. This 
5-year trial of Deworming and Enhanced Vitamin A 
supple mentation (DEVTA) in 1 million pre-school 
children was larger than all other vitamin A trials 
combined. Its primary aim was to assess eﬀ ects of a 
standard periodic treatment regimen on mortality at 
ages 1·0–6·0 years.17
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Early analyses of the DEVTA vitamin A mortality 
ﬁ ndings were presented in 2007, have been available 
online ever since,18 and have been partly included in 
recent meta-analyses.19–24 Here we report ﬁ nal analyses of 
the DEVTA vitamin A ﬁ ndings, which are more robust 
than those (unpublished) early analyses and include 
more reliable estimates of compliance, plasma retinol 
concentrations, and the proportional eﬀ ects on child 
mortality, which is the main endpoint. This report 
focuses on the vitamin A (ie, retinol) results. An accom-
panying report17 of the albendazole results includes fuller 
details of study logistics.
Methods
Study design
The unit of randomisation in this cluster-randomised trial 
was the block, a state administrative unit that generally 
has a rural population of more than 100 000. 36 blocks 
were cluster-randomly allocated retinol supple mentation 
every 6 months for 5 years and 36 open control (ﬁ gure 1). 
All were within a few hours of the main study centre in 
Lucknow, the Uttar Pradesh state capital. The study was 
approved by King George’s Medical University ethics 
committee (Lucknow, India) and by the ICDS directors in 
each block, but no permissions were obtained from the 
population, except when blood samples were sought.
Within the participating blocks, the study population 
was all young children living in the deﬁ ned catchment 
areas of 8338 village anganwadi child-care centres 
(AWCs; anganwadi means courtyard) that the ICDS 
regarded as functional (except in one block17) (ﬁ gure 1). A 
typical rural AWC employs an ICDS-funded AWC child-
care worker and serves a village with a population of 
about 1000 (with 10–15% aged 1·0–6·0 years); large 
villages can have more AWCs. AWCs register about two-
thirds of the children of age 1·0–5·0 years (and one-third 
of 5-year-olds) for possible nutritional supplementation.
In a typical block these study catchment areas in-
cluded about 10 000–20 000 pre-school children of age 
1·0–6·0 years, so at any one time the study included 
1 million such children. As the study began it had a 
million participants, and during it another million 
1-year-olds joined it and a million 6-year-olds left 
(ﬁ gure 2), so at one time or another it included about 
2 million children. The study continued for 5 years 
(5 million child-years), and recorded 25 000 child deaths 
at ages 1·0–6·0 years.
Randomisation and masking
Neighbouring blocks (clusters), in groups of four (where 
possible in the same district), were randomly allocated in 
Oxford, UK, using a factorial design, to: (1) usual care; 
(2) 6-monthly vitamin A; (3) 6-monthly albendazole; or 
(4) both. No placebos were used; the control was open. 
Apart from the district each block was in, no relevant 
details of it were known to those generating the random 
allocation. This report compares retinol (36 blocks) 
versus not (36 blocks), largely ignoring albendazole 
allocation and stratum.
Procedures
The Sight and Life Foundation, funded by Roche (Basel, 
Switzerland), donated standard Roche capsules of 
200 000 IU retinyl acetate in oil, to be cut and dripped 
into the child’s mouth. Dosage was independent of age. 
When treatment became due (in April or October), in 
each treatment-allocated block a mass-treatment day 
was selected on which all children of apparent age 
6–72 months in all study AWCs in that block would be 
given the trial treatment by their AWC worker. Those 
treated were checked oﬀ  on the AWC lists, and the few 
children missed were often found by the AWC worker 
and treated soon afterwards.
On all mass-treatment days, unannounced visits were 
made to every fourth AWC on a numbered list to check 
that distribution had started. During the third study 
year, monitors abstracted from local records name, sex, 
age, and father’s name for all (just over 1 million) 
Of 118 administrative blocks in the seven DEVTA districts in north India,  
46 with many AWCs not functioning in 1998 were not included. 
72 blocks remained; parts of each of them became the study areas 
(ie, the catchment areas of the 8338 AWCs that were originally 
identiﬁed before random allocation as functional, and followed up*)
Randomisation by block (balanced in groups of four neighbouring blocks) 
36 vitamin A blocks (200 000 IU×11,
6-monthly, April 1999–April 2004),
 with 4233 AWCs functional 
36 open control blocks (no
placebo tablets), with 
4278 AWCs functional
91 AWCs (2%) lost 
to follow-up*
82 AWCs (2%) lost
to follow-up*
36 vitamin A blocks, with 4142 AWCs 
followed up
36 control blocks, with 
4196 AWCs followed up
11–14 6-monthly non-treatment visits scheduled to each AWC (ﬁrst before 
May, 1999, last after April, 2004) to record all deaths during this period
Total 100 654 visits to 8338 AWCs, with 97 231 infant deaths plus 
15 589 deaths at ages 1·0–2·9 years and 9993 at ages 3·0–6·0 years
NB Main treatment comparisons (based on cluster randomisation) compared 
72 block-speciﬁc average numbers of deaths per AWC
Figure 1: Flow diagram for the 72 mainly rural administrative blocks 
randomly allocated 5 years of 6-monthly vitamin A or open control
AWC: anganwadi (ie, courtyard) child-care centre. In these 72 blocks, 
8338 child-care centres were followed up, with total population at ages 
1·0–6·0 years 1 million and 5 million child-years at risk in the 5 years between 
May, 1999, and April, 2004. *AWC catchment areas correspond approximately 
to villages; it was determined before randomisation which AWCs were then 
functional, and hence potential study areas; loss of an AWC to follow-up was 
deﬁ ned by having only 1–6 follow-up visits (mean only 3, as against 12 in 
included AWCs), and was generally because the AWC had ceased to function.
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pre-school children in the study areas (logistic details in 
accompanying report17). This mid-study census was 
used before each subsequent mass-treatment day to list 
all in 25 AWCs per block with predicted age 12–70 months 
(ie, well within the range to be treated); monitors 
established soon after whether those listed had actually 
been treated, and whether they were currently registered 
with the AWC.
Annually, Oxford randomly selected one AWC per 
block for ﬁ eldwork teams to survey 30 pre-school children 
(six per year of age) 1–5 months after a mass-treatment 
day, seeking from them blood and faecal samples. In 
practice, full information with com plete assay results 
was obtained for about 24 children per block. The 
children surveyed were not randomly chosen and were 
often taken from AWC lists, hence mainly registered 
with the AWC. Caregivers were asked whether the 
previous mass treatment had been received (and, if so, 
whether any acute illness followed) and about recent 
(past 4 weeks) illnesses.
Fieldworker teams were trained to seek Bitot’s spots 
and measure ﬁ nger-prick haemoglobin. Venous blood 
in 5 mL EDTA vacutainers was transported chilled to 
Lucknow, separated next morning (15 min at 3500 rpm), 
stored at –20°C then ﬂ own on dry ice to Oxford for 
storage at –80°C and retinol assay (appendix). Despite 
low retinol concen trations, individual measurements 
were reproducible, so the diﬀ erence in plasma retinol 
with treatment allocation could be measured reliably. 
Retinol assay results were, however, available only after 
mid-study because earlier samples were biologically 
contaminated in storage and were unmeasurable.
Deaths were recorded by 18 full-time motorcycle 
village-to-village monitors.17 Monitors covered four neigh-
bouring blocks at a time, one in each treatment group, 
and within 6 months went to all (roughly 500) study 
AWCs in those blocks to identify and visit all households 
where in the past year a liveborn infant or child younger 
than 10 years had died, recording age (often given only 
approximately, so our analyses of mortality at 
1–5 completed years of age include all deaths at recorded 
ages 1·0–6·0 years), sex, name, parental names, and (by 
simple verbal autopsy) likely cause.
6 months later a diﬀ erent monitor visited the same 
blocks, again to record all deaths in the past year, so each 
death should have been reported twice, independently. 
Monitors knew supervisors would, with 5% probability, 
randomly re-study selected villages shortly afterwards to 
ensure relevant households had all been visited (and to 
help to consolidate monitors’ discipline and methodology).
Statistical analysis
The prespeciﬁ ed primary analysis was of pre-school child 
mortality (appendix), operationalised because of digit 
preference in stating ages to mortality at reported ages 
1·0–6·0 years during the 5-year study period (sec ondarily 
subdivided into ages 1·0–2·9 and 3·0–6·0 years, and into 
study years 1–2 and 3–5). Analyses of eﬀ ects of vitamin A 
allocation on any category of mortality (or on any other 
outcomes) derived only from the 72 block averages for the 
outcome or explanatory factors of interest, giving all 
blocks equal weight because they were of similar size.
Mortality analyses calculated for each block the mean 
number of child deaths recorded per study AWC and the 
mean number of infant deaths recorded per study AWC. 
Analyses of eﬀ ects on child mortality (reﬂ ecting the 
cluster-randomised design) then regressed child deaths 
per AWC (72 values, one per block) on retinol allocation 
(0/1), with simultaneous adjustment for albendazole 
allocation (also 0/1), an interaction term (±1, included 
only in simultaneous analyses of both treatments) and 
infant deaths per AWC (an important explanatory factor 
that cannot have been materially aﬀ ected by trial treat-
ment and varied two-fold between blocks). Sensitivity 
analyses explored the relevance of not adjusting for 
infant mortality or of additional adjustment for district 
(by which randomisation had been stratiﬁ ed). All these 
analyses did not depend on the mid-study census, but 
further sensitivity analyses explored the eﬀ ect of 
adjusting for the mid-study census estimate of child 
population per AWC (an unimportant factor, as it varied 
little between blocks).
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Date
Born May, 1995
and hence in DEVTA
May, 1999–April, 2001
Born May, 1998
and hence in DEVTA
May, 1999–April, 2004
Born May, 2001
and hence in DEVTA
May, 2002–April, 2004
↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
↑ Treatment month: every 6 months (in April and October), trial treatment was to be given to 
all (about 500 000) then of age 6 months to 6 years in the study areas allocated vitamin A 
Twice yearly (in between the treatment months, and after the last one), each village was visited 
(>100 000 visits), recording >97 000 infant deaths and >25 000 deaths at ages 1·0–6·0 years
For each of the 72 blocks, one village per year was randomly selected and visited to survey
30 children and seek from them blood and faecal samples (with technically successful results only from
October, 2001) 
Figure 2: Times when treatment was to be given and mortality monitored, and range of ages (1·0–6·0 years) 
and dates (May, 1999–April, 2004) for inclusion in main analyses of child mortality
Shaded area indicates more than 2 years’ treatment already received. Diagonal lines describe involvement of 
children born on May 1 in 1995, 1998, and 2001. With 1 million children of age 1·0–6·0 years at any one time, 
5 million child-years at risk are included.
See Online for appendix
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Further logistic and statistical details are described 
elsewhere, including power calculations;17 if, as suggested 
by previous trials, treatment reduced mortality by at least 
20% there was 95% chance of achieving p<0·01. SAS 
version 9.1 was used. This trial is registered at 
ClinicalTrials.gov, NCT00222547.
Role of the funding sources
Study sponsors had no role in design, conduct, analysis, 
or interpretation. SA, RP, DB, and SR had full data access 
and entirely controlled submission for publication.
Results
Compliance with treatment allocation was good. Un-
announced visits to a quarter of the AWCs in vitamin A 
blocks on or just after each mass-treatment day found 99% 
(10 925/11 090 visits) were distributing treat ment. Indepen-
dently, enquiries a week after mass-treatment days about 
lists of named children from the mid-study census 
conﬁ rmed supplementation of 96% (133 602/138 966) of 
those registered with the AWC and 72% (80 048/111 227) of 
those not, largely independent of age (data not shown). 
Because two-thirds of under-5s and one-third of 5-year-olds 
were AWC-registered, overall compliance was about 86% 
(not 91%, as previously estimated18). Consistent with this 
ﬁ nding, the biomedical surveys of randomly chosen 
AWCs, which tended to over-sample AWC-registered chil-
dren, found caregivers report ing 91% (2337/2581) had 
received retinol on the previous mass-treatment day. On 
one occasion in mid-study, polio vaccine plus retinol was 
Ages 1·0–2·9 years Ages 3·0–6·0 years Ages 1·0–6·0 years
Vitamin A 
(n=810)
Control 
(n=775)
95% CI for 
diﬀ erence
Vitamin A 
(n=1771)
Control 
(n=1809)
95% CI for 
diﬀ erence
Vitamin A 
(n=2581)
Control 
(n=2584)
95% CI for 
diﬀ erence
Biomedical measurements
Retinol
All participants (μmol/L) 0·70* 0·63 –0·11 to –0·04 0·73† 0·61 –0·15 to –0·09 0·72† 0·62 –0·13 to –0·08
Boys (μmol/L) 0·71‡ 0·63 –0·12 to –0·03 0·73† 0·62 –0·15 to–0·08 0·72† 0·62 –0·14 to –0·07
Girls (μmol/L) 0·70‡ 0·64 –0·11 to –0·02 0·74† 0·61 –0·15 to–0·09 0·72† 0·62 –0·13 to –0·08
Retinol <0·35 μmol/L (%) 6·9%§ 11·9% 1·2 to 8·7 5·7%† 13·6% 5·1 to10·7 6·4%† 13·3% 4·2 to 9·6
Retinol <0·70 μmol/L (%) 50·9%§ 61·9% 4·7 to 17·5 47·0%† 65·6% 13·4 to 23·7 48·7%† 64·8% 11·4 to 20·9
Haemoglobin (g/L) 95·4 94·9 –2·4 to 1·5 103·6 103·3 –1·9 to 1·3 99·7 99·3 –1·8 to 1·0
Weight (kg) 9·39 9·47 –0·10 to 0·26 12·68 12·72 –0·14 to 0·21 11·04 11·09 –0·09 to 0·19
Height (cm) 74·5 74·3 –0·8 to 0·4 88·7 88·7 –0·7 to 0·6 81·7 81·5 –0·7 to 0·4
BMI (kg/m²) 16·9 17·1 –0·1 to 0·6 16·1 16·1 –0·2 to 0·2 16·5 16·6 –0·1 to 0·3
Eye problems (% prevalence)
Bitot’s spots 1·0% 1·8% –0·5 to 2·1 2·2%‡ 4·8% 0·9 to 4·3 1·4%‡ 3·5% 0·8 to 3·4
Bitot’s spots or night blindness 1·0% 1·9% –0·5 to 2·1 2·3%‡ 5·0% 0·9 to 4·3 1·5%‡ 3·6% 0·8 to 3·4
Boys 1·8% 1·7% –1·7 to 1·7 3·8% 6·0% –0·4 to 4·9 2·7% 4·5% –0·2 to 3·7
Girls 0·6% 2·4% –0·5 to 4·2 1·0%‡ 3·8% 0·9 to 4·6 0·4%‡ 2·9% 1·0 to 3·9
Bitot’s spots, night blindness, 
or conjunctivitis in past 4 weeks
2·3% 4·6%  0·5 to 4·1 3·9%‡ 7·4% 1·4 to 5·6 3·0%* 6·2% 1·4 to 4·9
Illness in past 4 weeks (% prevalence)
Conjunctivitis 1·3% 2·9% 0·1 to 3·1 1·6% 2·7% –0·1 to 2·4 1·5%§ 2·8% 0·2 to 2·4
Diarrhoea 39·0% 44·1% –1·8 to 12·0 32·2% 34·5% –2·2 to 6·9 36·1% 39·0% –1·3 to 7·1
Cough 17·1% 20·5% –1·3 to 8·1 17·5% 18·0% –2·8 to 3·8 17·5% 19·0% –1·8 to 4·7
Runny nose 13·8% 13·6% –5·5 to 5·2 10·4% 11·7% –1·9 to 4·5 11·5% 12·6% –2·1 to 4·1
Fast breathing 3·7% 5·0% –1·1 to 3·7 2·3%‡ 4·1% 0·6 to 3·1 2·8%§ 4·4% 0·4 to 2·8
Diﬃ  cult breathing 3·6% 4·5% –1·3 to 3·1 2·3% 3·5% 0·0 to 2·4 2·9% 3·9% –0·2 to 2·2
Noisy breathing 2·7% 3·0% –1·7 to 2·3 1·9% 2·3% –0·7 to 1·5 2·2% 2·7% –0·6 to 1·5
Measles 1·8% 1·4% –1·6 to 0·9 1·3% 0·6% –1·6 to 0·3 1·5% 1·0% –1·4 to 0·3
Fever 34·1% 35·3% –4·2 to 6·6 28·0% 28·6% –3·3 to 4·6 30·4% 31·3% –2·5 to 4·3
Skin infection 14·0% 14·6% –3·4 to 4·5 12·4% 15·0% –1·1 to 6·3 13·2% 15·1% –1·5 to 5·3
Biomedical visit to one random village per block per year (from mid-study): 5165 children with no data missing. Data from examination of children and caregiver interviews. 
Each entry is the mean of 36 block-speciﬁ c values. The 95% CIs reﬂ ect possible eﬀ ects of randomly choosing 36 out of the 72 block-speciﬁ c values, ignoring the stratiﬁ cation. 
Results are standardised to ages 2·0, 4·0, or 3·0 years, respectively, for ages 1·0–2·9, 3·0–6·0, or 1·0–6·0 years, and to 50:50 averages for half-year season (dry/wet). Height, 
weight, and body-mass index (BMI) are further standardised for study half-years. Except where indicated, results are standardised 50:50 for sex. Compliance with previous 
vitamin A dosage was 90% in these children, but about 86% in all children allocated vitamin A. *p<0·001. †p<0·00001. ‡p<0·01. §Two-sided p<0·05.
Table 1: Eﬀ ects of vitamin A allocation on plasma retinol, haemoglobin,  weight, height, Bitot’s spots, and recent ill health (generally as reported by the 
child’s guardian) in a subsample from each of the 72 blocks during the second half of the study, by age
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supposed to be given to all children in the study districts; 
other than this event, there was little non-trial retinol 
supplementation. Loss to follow-up was similarly 
uncommon in both treat ment arms (ﬁ gure 1), and was 
generally due to AWC closures.
Allocation to retinol halved the prevalence of severe 
deﬁ ciency 1–5 months after mass-treatment days. Retinol 
assays were available (only during the second half of the 
study) for 5165 children with complete information on all 
assays and questionnaire replies, 2581 in retinol-allocated 
versus 2584 in control blocks (table 1). Among them, 
mean retinol was 0·72 (SE 0·01) μmol/L versus 
0·62 (0·01) μmol/L, a 16% increase (p<0·00001). These 
retinol values are both 1·2 times higher (see appendix) 
than the uncalibrated values reported previously.18 Since 
compliance with the previous mass supplementation 
was 91% in children who gave blood, but only 86% 
overall, the proportional increase in plasma retinol in the 
whole study population in retinol-allocated blocks was 
about 15%. Among those whose blood was tested, the 
prevalence of severe vitamin A deﬁ ciency (retinol 
<0·35 μmol/L) was 6% versus 13%. Haemo globin, 
weight, and height were not signiﬁ cantly aﬀ ected.
The prevalence of Bitot’s spots (1·4% vs 3·5%) was 
also halved, as was that of conjunctivitis within the 
past 4 weeks. Night blindness is diﬃ  cult to assess in 
young children, and was uncommon in the absence of 
Bitot’s spots. The proportion with any of these eye 
problems was 3·0% versus 6·2% (p<0·001). Of other 
indices of recent ill health, only chest infection with 
fast breathing was signiﬁ cantly reduced (2·8% vs 4·4%, 
p=0·03 [not signiﬁ cant with Bonferroni correction for 
multiple comparisons]).
During the entire study, monitors recorded 97 231 live-
born infant deaths (86 084 before age 6 months) and 
25 582 child deaths at ages 1·0–6·0 years (ﬁ gure 1). 
This ﬁ gure includes any extra deaths identiﬁ ed by a 
special mid-study retrospective enquiry (which found 
similar numbers of missed child deaths in the two 
treatment groups, suggesting little ascertainment bias). 
Numbers of infant and child deaths per AWC in 
diﬀ erent blocks are plotted against each other in 
ﬁ gure 3. The mean number of infant deaths per AWC 
was 11·7 (SD 1·8), the mean number of child deaths per 
AWC was 3·1 (SD 0·7), and there was a strong (0·69) 
correlation between the numbers of infant and child 
deaths per AWC in diﬀ erent blocks.
Because any trial treatment in infancy began at around 
9 months of age and most infant deaths occur much 
earlier, infant mortality cannot have been materially 
aﬀ ected by it. Hence, this strong correlation reﬂ ects 
diﬀ erences between low-risk and high-risk blocks that 
have nothing to do with trial treatment and that 
substantially aﬀ ect both infant and child mortality 
(conﬁ rming this conclusion, the correlation between 
infant and child mortality was equally strong among 
blocks that had all had the same treatment; ﬁ gure 3 
legend). We therefore used the number of infant deaths 
as an explanatory factor to reduce chance variation in our 
main analyses of the eﬀ ects of treatment allocation on 
the number of child deaths (see Methods; mortality at 
ages 0–6 months had correlation 99·3% with infant and 
68·2% with child mortality).
Table 2 shows the ﬁ ndings for child mortality at ages 
1·0–2·9 years, 3·0–6·0 years, and 1·0–6·0 years, along 
with the relative risk for the age range 1·0–6·0 years. 
Deaths per child-care centre at ages 1·0–6·0 years during 
the 5-year study (the primary trial endpoint) were 
3·01 retinol versus 3·15 control (absolute reduction 0·14 
[SE 0·11], mortality rate ratio [RR] 0·96, 95% CI 
0·89–1·03, p=0·22), suggesting absolute risks of death 
between ages 1·0 and 6·0 years of approximately 2·5% 
retinol versus 2·6% control. Although this ﬁ nding 
suggests that overall child mortality was 4% lower in 
vitamin A than in control blocks, this 4% reduction 
includes the possibility of no beneﬁ t and the possibility 
of appreciable beneﬁ t (95% conﬁ dence limit for reduction 
11%). For, there is two-fold variation in block mortality 
rates (ﬁ gure 3), and randomisati on was by block rather 
than by AWC or by individual.
Sensitivity analyses (table 2) showed that the RR had 
been little changed (although its CI was narrowed) by 
the adjustment for infant deaths, and would be little 
changed by further adjustment for district or for mean 
number of children per AWC. The RR for the apparent 
eﬀ ects of retinol on child mortality was much the same if 
neither group got albendazole as it was if both groups 
got albendazole (interaction p=0·83). So, the RR was 
little changed (although its CI was widened) by 
restrict ing attention to 18 retinol-plus-albendazole versus 
0 4 (3%) 8 (6%) 12 (9%) 16 (12%)
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2·5%
Figure 3: Correlation between 72 block-speciﬁ c average numbers of infant 
and child deaths per child-care centre (AWC) during the entire study
The inter-block correlation (illustrated here) between numbers of infant and 
child deaths per AWC was 68·7% ignoring trial treatment allocation (or 68·4% 
given the four-way allocation to albendazole, retinol, both or neither), and 
ranged from 66–71% within the four treatment groups. Mortality at ages 
0–6 months had correlation 99·3% with infant and 68·2% with child mortality.
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18 albendazole-alone blocks, where monitoring could not 
be biased by one group getting no treatment.
For no speciﬁ c disease category was the RR signiﬁ cantly 
aﬀ ected by the vitamin A allocation, although again the 
ﬁ ndings include the possibility of appreciable beneﬁ t 
and of no beneﬁ t. For diarrhoeal mortality (28% of all 
deaths) the RR was 0·94 (95% CI 0·83–1·06) and for 
measles mortality (6% of all deaths), which varied 
particularly widely between blocks, the RR was 0·91 
(0·70–1·19). The annual number of deaths per AWC was 
greater at ages 1·0–2·9 than 3·0–6·0 years (particularly 
for diarrhoea, pneumonia, and malnu trition), greater in 
girls than in boys, and greater during the earlier than the 
later study years. For no category of disease, age, sex, or 
time period, however, was there a clearly signiﬁ cant 
eﬀ ect of vitamin A allocation on child mortality (table 2). 
Even for those on treatment more than 2 years (ages 
3·0–6·0 years in last 3 study years; ﬁ gure 2) there was no 
signiﬁ cant diﬀ erence in mortality between blocks allo-
cated vitamin A and control.
Our mid-study census enumerated about 119 chil dren 
of age 1·0–6·0 years per AWC (65 male, 54 female), 
with little variation between blocks (coeﬃ  cient of 
variation 4·6%). This suggests absolute risks of 
death between ages 1·0 and 6·0 years of 2·5% retinol 
versus 2·6% control. If our census under-enumerated 
children, all the absolute risks in the last column of 
table 2 should be increased by a common factor, without 
aﬀ ecting the ratios of the absolute risks to each other. 
In table 2 the overall numbers of child deaths per AWC 
and the mortality rate ratios are completely independent 
of our mid-study census of the child population per 
AWC, the ﬁ ndings from which aﬀ ect only the estimates 
of absolute risk in the right-hand column.
Retinol administration was not associated with any 
immediate serious adverse eﬀ ects. In the 36 retinol-
allocated blocks, 356 children died during the 7 days 
before mass-treatment was due and 354 during the next 
7 days (rate 0·4% per year, suggesting no immediate 
hazard). Caregivers were asked at biomedical surveys 
whether the previous treatment had been closely fol-
lowed by any apparent illness; no material diﬀ erences in 
vomiting, diarrhoea, or fever were seen, after allowing 
for the clustering of childhood infection outbreaks.17
Discussion
If considered in isolation from the previous community-
based trials of vitamin A and child mortality, the present 
analyses of DEVTA yield only a non-sig niﬁ cant mortality 
reduction. This result was unexpected, given that 
several1,3–5,7,8 of the previous trials had reported a 
signiﬁ cant mortality reduction. In interpretation of 
Number of child deaths recorded per AWC during the whole study, vitamin A versus control 
(A vs C) and 95% CI for the diﬀ erence (C–A)*
Mortality rate ratio 
(RR=A/C), age 
1·0–6·0 years
Absolute risk of 
death from age 
1·0–6·0 years (%)
Age 1·0–2·9 years Age 3·0–6·0 years Age 1·0–6·0 years RR 95% CI Vitamin A Control
A C CI for (C–A) A C CI for (C–A) A C CI for (C–A)
Cause of death
Diarrhoea 0·54 0·56 –0·04 to 0·09 0·29 0·33 –0·02 to 0·09 0·83 0·89 –0·05 to 0·16 0·94 0·83 to 1·06 0·70% 0·75%
Pneumonia 0·33 0·32 –0·05 to 0·04 0·12 0·12 –0·03 to 0·02 0·45 0·44 –0·07 to 0·05 1·02 0·89 to 1·18 0·38% 0·37%
Measles 0·10 0·13 –0·01 to 0·06 0·09 0·08 –0·04 to 0·02 0·19 0·21 –0·04 to 0·07 0·91 0·69 to 1·19 0·16% 0·18%
Other infection/unknown 0·57 0·61 –0·05 to 0·12 0·42 0·46 –0·03 to 0·10 0·99 1·07 –0·06 to 0·21 0·93 0·82 to 1·06 0·83% 0·90%
Malnutrition 0·19 0·18 –0·05 to 0·03 0·05 0·06 –0·01 to 0·02 0·24 0·24 –0·06 to 0·05 1·02 0·82 to 1·27 0·21% 0·20%
Other or external 0·11 0·11 –0·03 to 0·02 0·18 0·19 –0·02 to 0·04 0·30 0·30 –0·04 to 0·05 0·98 0·84 to 1·15 0·25% 0·26%
All causes, by subgroup
Boys 0·85 0·85 –0·08 to 0·07 0·58 0·60 –0·05 to 0·09 1·43 1·44 –0·10 to 0·14 0·99 0·91 to 1·07 2·20% 2·22%
Girls 0·99 1·06 –0·02 to 0·16 0·59 0·64 –0·00 to 0·11 1·58 1·70 –0·00 to 0·24 0·93 0·86 to 1·00 2·92% 3·15%
May, 1999–April, 2001 (2 years) 0·84 0·87 –0·05 to 0·11 0·55 0·58 –0·02 to 0·10 1·39 1·46 –0·05 to 0·18 0·96 0·88 to 1·03 2·92% 3·06%
May, 2001–April, 2004 (3 years) 1·00 1·04 –0·06 to 0·14 0·62 0·65 –0·05 to 0·12 1·62 1·69 –0·10 to 0·25 0·96 0·86 to 1·06 2·26% 2·37%
Trial albendazole 1·77 1·93 –0·03 to 0·36 1·15 1·15 –0·17 to 0·16 2·92 3·08 –0·15 to 0·48 0·95 0·85 to 1·05† 2·45% 2·59%
No trial albendazole 1·92 1·89 –0·23 to 0·17 1·18 1·32 –0·02 to 0·31 3·10 3·21 –0·20 to 0·43 0·96 0·87 to 1·06† 2·60% 2·70%
All causes, total‡ 1·84 1·91 –0·07 to 0·21 1·16 1·24 –0·05 to 0·19 3·01 3·15 –0·08 to 0·36 0·96 0·89 to 1·03§ 2·53% 2·64%
*Reduction (C–A) in number of child deaths per AWC and its standard error, s, were calculated by regression of 72 block-speciﬁ c numbers of child deaths per AWC on vitamin A allocation (0/1), albendazole 
allocation (also 0/1), and on the block-speciﬁ c numbers of infant deaths per AWC (to help to correct for any pre-existing variation in prognosis. RR is then A/C with 95% CI (A – x)/(C + x) to (A + x)/(C – x), where 
x=1·96s/2. Assuming approximately 119 (65 male, 54 female) children per AWC at ages 1·0–6·0 years, approximate absolute 5-year risks were calculated as 5 times (annual deaths per AWC)/(119, 65, or 54, as 
appropriate). Sensitivity analyses: further inclusion of district (as six indicators) or child population per AWC (which varied little) had no material eﬀ ect. †Interaction p=0·83. ‡Mortality at ages 1–6 months had 
correlation 99·3% with infant and 68·2% with child mortality, so results were unchanged if it was used instead of infant mortality to correct for initial variation in prognosis; without either correction, numbers 
of child deaths per AWC at ages 1·0–2·9, 3·0–6·0, and 1·0–6·0 years would have been, respectively, 1·87 versus 1·88 (p=0·96), 1·18 versus 1·22 (p=0·50), and 3·05 versus 3·10 (p=0·74); RR 0·98 (0·89–1·08); 
absolute risks 2·56% versus 2·61%. §2-sided p=0·22.
Table 2: Eﬀ ects of albendazole allocation on pre-school child mortality: absolute numbers of deaths per anganwadi child-care centre (AWC) by allocated treatment, albendazole versus 
control (A vs C), and, from these, mortality rate ratio (A/C) and approximate absolute risk of death from age 1·0 to 6·0 years
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DEVTA, however, the key ﬁ nding is not the mortality rate 
ratio of RR 0·96, but its 99% CI (0·87–1·05; ﬁ gure 4). 
This CI is readily compatible both with zero eﬀ ect and 
with prevention of somewhat more than 10% of all child 
mortality, but excludes prevention of much more than 
13% of child mortality (panel).
DEVTA (1 million participants at any one time, 
2 million ever) was larger than all the other trials 
combined and it was reliably conducted, with an average 
of about 86% compliance with 6-monthly supplemen-
tation and careful, unbiased ascertainment of child 
mortality. Furthermore, conventional indications for 
supplementation were present, since the control group 
had mean retinol 0·62 μmol/L and appreciable preva-
lences of severe biochemical vitamin A deﬁ ciency (retinol 
<0·35 μmol/L) and of Bitot’s spots, which were both 
halved by allocation to vitamin A. Overall, mean plasma 
retinol increased by about 15% in children allocated 
vitamin A, an increase about as great as in the largest 
previous trial.7,8 Higher or more frequent doses might 
have had greater eﬀ ects, but the regimen we tested is the 
one that is currently recommended internationally.
Initial analyses, presented orally in 2007,18 had also 
indicated a mortality ratio of 0·96, but were based on the 
estimated death rate in each block, which depended on 
our mid-study estimate of the number of children. In 
unpublished discussions of those initial analyses it was 
noted that errors in census methods might aﬀ ect this 
denominator. We therefore undertook extensive further 
data checks—thereby eliminating a few duplicate 
records—and the mortality ratios in table 2 are now 
robustly based on the average number of deaths per AWC 
in each of the 72 blocks, which does not depend at all on 
knowledge of the AWC populations.
Single trial results should generally be considered not 
on their own, but together with all other randomised 
evidence.25,26 The most appropriate method of combining 
evidence from diﬀ erent trials is generally to take a 
weighted average of their results that gives proportion-
ately more weight to those that are more reliable. To 
minimise the eﬀ ects of chance on the weighted average, 
the weight given to each result should be inversely 
proportional to the variance of that result (yielding the 
inverse-variance-weighted average). Figure 4 shows the 
published results from the eight other trials1–8 (with the 
99% CI for each calculated from the 95% CI), and gives an 
inverse-variance-weighted average of these eight results 
(RR 0·77, 99% CI 0·68–0·89; appendix p 9). The CIs 
generally1,3–8 allowed for any clustering. A recent Cochrane 
review of these eight previous trials plus the single-dose 
and smaller trials yielded a pooled RR of 0·76.21,22
Year trial published, author 
or trial name, country
Mortality RR (95% CI*)
0·66 (0·44–0·97)
1·00 (0·65–1·55)
0·46 (0·30–0·71)
0·70 (0·56–0·88)
0·74 (0·55–0·99)
1·06 (0·82–1·37)
0·30 (0·12–0·75)
0·81 (0·68–0·98)
0·89 (0·84–0·95)
Equivalent numbers of deaths† Mortality RR
41 vs 62
40 vs 40
30 vs 66
128 vs 183
77 vs 105
120 vs 113
6 vs 20
208 vs 257
650 vs 846
1472 vs 1540
2122 vs 2386
1986, Sommer, Indonesia1
1990, Vijayaraghavan, India2
1990, Rahmathullah, India3
1990, West, Nepal4
1992, Daulaire, Nepal5
1992, Herrera, Sudan6
1992, Arthur, Ghana7,8
1993, VAST, Ghana8
1986–93, subtotal (8 trials)‡
2013, DEVTA, India
Total (DEVTA+8 others)‡
0·50 0·75 1·00 1·25 1·50
0·77 (99% CI 0·68–0·89)
0·96 (99% CI 0·87–1·05)
0·89 (SE 0·03) 
p=0·00015
99% or 95% confidence interval Vitamin A Control
Figure 4: Published results from the eight large previous trials of regular vitamin A supplementation and child mortality, DEVTA results, and weighted 
averages of results from the other eight trials and from all nine trials
Heterogeneity between eight previous trials p=0·010; heterogeneity between DEVTA and subtotal of eight previous trials p=0·0010. Methods as in appendix p 9. 
Calculation of a weighted average does not assume the mortality rate ratios (RRs) in diﬀ erent studies are the same. The equivalent numbers of deaths are approximately 
additive when calculating weighted averages, but are not used in calculations. *95% CI to 2 dp derived from study publications. †Number of deaths (vitamin A vs control) 
in a large, 50:50 individually randomised trial that would yield the same RR and CI. Trials were excluded if they had a total of fewer than 20 such deaths, recruited patients 
with disease, or gave single-dose treatment. ‡From the inverse-variance-weighted average of log RR in each separate trial.
Panel: Research in context
Meta-analyses of the previous trials21,22 of periodic vitamin A 
supplementation in developing countries had suggested that 
supplementation could generally reduce childhood mortality 
by about 20–30%. DEVTA shows that the mortality reduction 
is not as great as previous trials had suggested, but does not 
show it is zero. (It also shows retinol supplementation is not 
followed by any acute increase in the risk of death.) An 
updated meta-analysis, based on an appropriately weighted 
average of the present and previous trials, now suggests that 
where vitamin A deﬁ ciency is widespread, but xerophthalmia 
is rare, the reduction in childhood mortality from full 
compliance with supplementation is likely to be about 5–15%, 
only about a quarter or half as great as previously suggested.
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Figure 4 also shows the result for DEVTA (RR 0·96) 
and for the aggregate of all nine trials (RR 0·89; appendix 
p 9). Calculation of a weighted average of several results 
does not implicitly assume that the real treatment eﬀ ect 
in all those trials is the same25,26 (hence, although the 
term ﬁ xed-eﬀ ect meta-analysis is sometimes used to 
describe such a weighted average, this usage is mis-
leading). Nevertheless, the apparent discrepancy be tween 
DEVTA and the weighted average of the other eight trial 
results is signiﬁ cant (p=0·001) and was unexpected, 
since there is no obvious reason to expect the treatment 
eﬀ ect to be much smaller in DEVTA than in most other 
trials. These apparently discrepant results need cautious 
inter pretation, especially in view of the current contro-
versies about vitamin A supplementation.23,24
It would not be appropriate to dismiss the previous trials 
and use DEVTA alone to argue that vitamin A supple-
mentation confers no net beneﬁ t in India; DEVTA does 
not exclude a reduction of more than 10% in child 
mortality, which would be an important beneﬁ t, and there 
is no good reason to ignore the deﬁ nite evidence of beneﬁ t 
from the aggregated results of the other eight trials.
Conversely, it would not be appropriate to dismiss the 
DEVTA result, or to conceal the reliability of it by a 
random eﬀ ects meta-analysis (which, when trials are of 
very diﬀ erent sizes, implicitly gives undue weight to 
small trials and insuﬃ  cient weight to large trials25,26). 
DEVTA contributes substantially more statistical infor-
mation than all previous trials put together, is directly 
relevant to current supplementation strategies, and its 
99% conﬁ dence limits exclude mortality reductions 
greater than 13%.
For illustrative purposes only, ﬁ gure 4 and appendix p 9 
give, along with each result, the equivalent number of 
deaths (vitamin A vs control) that would, if seen in a 
large, individually randomised (50:50) trial, yield the 
same RR and CI. Because the weights used were chosen 
to minimise the eﬀ ects of chance on the weighted aver-
age, these equivalent numbers of deaths are approxi-
mately additive when information from diﬀ erent trials is 
combined, which helps to clarify how much each trial 
contributes to the weighted average. (These illustrative 
numbers were, however, not used in any calculations.)
The weighted average of all nine results yields a RR of 
0·89 with 95% CI 0·84–0·95, p=0·00015. Thus, even if 
the beneﬁ ts of vitamin A supplementation were by 
chance exaggerated in the previous trial results, they are 
not zero. To interpret the randomised evidence, it is 
appropriate to bear in mind the apparent discrepancy 
between the results from DEVTA and from the average 
of the other eight trials, but also to bear in mind the 
overall result obtained by combining both (yielding a 
weighted average of all nine results). This ﬁ nding might 
well be the best guide to the proportional mortality 
reduction that should be expected in the future from 
reasonably good compliance with a programme of sup-
plementation in populations with widespread vitamin A 
deﬁ ciency that is not extreme enough to cause much 
risk of xerophthalmia.
In such moderately deﬁ cient populations, the cor-
responding absolute risk reduction (and hence the number 
needed to treat for 5 years to prevent one death) depends 
on the child mortality rate, which varies substantially from 
one such population to another and from one decade to 
another, so no estimate of it is given. Provisional acceptance 
of a weighted average of all the trial results might oﬀ er an 
evidence-based way forward from current arguments 
about whether the eﬀ ects of vitamin A supplementation 
on child mortality are substantial or negligible.23,24
The identical numbers of child deaths in DEVTA in 
the week before mass treatment and the next week is 
important evidence of safety, and suggests that the widely 
publicised observation from Assam27 of a number of deaths 
just after widespread retinol dosage was misleading.
Considering all of the randomised trial results, both 
the suggestion of no mortality reduction and the 
expectation of a large proportional mortality reduction 
are contradicted. The proportional reduction in child 
mortality achievable in such populations by good 
compliance with a programme of pre-school vitamin A 
supplementation is not zero, but it appears to be only 
about a quarter or half as great as the previous trials had 
suggested (perhaps 5–15%, to judge from the conﬁ dence 
interval for the weighted average of all trial results, rather 
than 20–30%). This, rather than the result of DEVTA 
alone or the results from the other eight trials without 
DEVTA, provides the most appropriate summary of the 
randomised evidence on the eﬀ ect of vitamin A on child 
mortality in this and many other populations.
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